Case Study: AstraZeneca generated DNA constructs in about 3 weeks at 50-90% lower cost with Benchling
Key results
The challenge
Rapid, scalable generation of DNA constructs is one of the most limiting first steps in early drug discovery, and the de novo synthesis of long coding sequences is a major time sink that modular cloning kits have not solved effectively. AstraZeneca needed a faster, lower-cost, and scalable way to generate constructs.
The solution
AstraZeneca developed a comprehensive DNA assembly framework using fragment recycling and integrated it into Benchling to support rapid, cost-efficient, and scalable construct generation.
The results, in context
According to Benchling's published account, AstraZeneca's DNA assembly framework generates constructs in an unheard-of 3 weeks and delivered cost savings from 50 to 90%. Fragment recycling significantly reduced DNA synthesis time and cost across the workflow.